CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorShanghai Ming Ju Biotechnology Co., Ltd.
About this trial
This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
Eligibility criteria
Qualifiers
≥18 years old;
Sign on the informed consent;
Subjects must have histologically confirmed Large B-cell Lymphoma;
Subjects had been treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT);
Disqualifiers
Primary CNS lymphoma;
History of another primary malignancy that has not been in remission for at least 2 years;
Subjects has HBV,HCV,HIV or syphilis infection at the time of screening;
Active deep venous thrombosis(DVT)/Pulmonary embolism(PE),or active DVT/PE requires anti-coagulation within 3 months prior to signing the ICF;
Trial design
Treatments tested in this trial
- Relma-cel
Treatment groups
12 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov